SeqLL Inc.
Atlantic International Corp., through its subsidiaries, operates as a staffing company servicing the commercial, professional, finance, direct placement, and managed service provider verticals. The company specializes in permanent, temporary, and temporary-to-permanent placement services in various areas, including accounting and finance, administrative and clerical, hospitality, information tech… Read more
SeqLL Inc. (ATLN) - Net Assets
Latest net assets as of September 2024: $16.22 Million USD
Based on the latest financial reports, SeqLL Inc. (ATLN) has net assets worth $16.22 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($135.64 Million) and total liabilities ($119.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.22 Million |
| % of Total Assets | 11.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 19.73 |
SeqLL Inc. - Net Assets Trend (2020–2023)
This chart illustrates how SeqLL Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SeqLL Inc. (2020–2023)
The table below shows the annual net assets of SeqLL Inc. from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $607.74K | -86.08% |
| 2022-12-31 | $4.37 Million | -46.63% |
| 2021-12-31 | $8.18 Million | +312.30% |
| 2020-12-31 | $-3.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SeqLL Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1342598200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00 | 0.00% |
| Other Components | $24.74 Million | 4071.46% |
| Total Equity | $607.74K | 100.00% |
SeqLL Inc. Competitors by Market Cap
The table below lists competitors of SeqLL Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The E W Scripps Co
STU:SQ6B
|
$35.64K |
|
VH Global Energy Infrastructure Ord
LSE:ENRG
|
$35.64K |
|
ECOBANK GHANA LIMITED
GSE:EGH
|
$35.66K |
|
Unicorn Technologies - Limited Partnership
TA:UNCT
|
$35.69K |
|
PORT OF TAURANGA LTD ORD
BE:PKF1
|
$35.63K |
|
EHEALTH
BE:M5V
|
$35.61K |
|
Tvardi Therapeutics, Inc.
NASDAQ:TVRD
|
$35.57K |
|
MCNCF
OTCGREY:MCNCF
|
$35.54K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SeqLL Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 4,366,886 to 607,743, a change of -3,759,143 (-86.1%).
- Net loss of 5,627,591 reduced equity.
- New share issuances of 1,800,000 increased equity.
- Other comprehensive income decreased equity by 22,451.
- Other factors increased equity by 90,899.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.63 Million | -925.98% |
| Share Issuances | $1.80 Million | +296.18% |
| Other Comprehensive Income | $-22.45K | -3.69% |
| Other Changes | $90.90K | +14.96% |
| Total Change | $- | -86.08% |
Book Value vs Market Value Analysis
This analysis compares SeqLL Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.34x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-13.18 | $3.79 | x |
| 2021-12-31 | $27.54 | $3.79 | x |
| 2022-12-31 | $13.21 | $3.79 | x |
| 2023-12-31 | $1.62 | $3.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SeqLL Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -925.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 7.30x
- Recent ROE (-925.98%) is below the historical average (-266.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -317.26% | 0.47x | 0.00x | $-659.94K |
| 2021 | -45.26% | -1763.64% | 0.02x | 1.31x | $-4.52 Million |
| 2022 | -93.77% | -5205.80% | 0.01x | 1.93x | $-4.53 Million |
| 2023 | -925.98% | 0.00% | 0.00x | 7.30x | $-5.69 Million |
Industry Comparison
This section compares SeqLL Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,014,663,689
- Average return on equity (ROE) among peers: -19.69%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SeqLL Inc. (ATLN) | $16.22 Million | 0.00% | 7.36x | $35.63K |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |